Medical device maker Medtronic said on Friday it would buy Intersect ENT Inc for $936.2 million in cash as it looks to bolster its offerings for ear, nose and throat procedures.
The Dublin, Ireland-headquartered company will buy all outstanding shares of Intersect for $28.25 per share, representing a premium of 15.2% to Intersect's closing price on Thursday.
Medtronic said Intersect's sinus implants would add to its portfolio of devices used by surgeons in the treatment of chronic rhinosinusitis — a common condition characterized by swelling in cavities, or sinuses, in the nose and head. Chronic rhinosinusitis affects more than 35 million adults per year in the United states.
Intersect's Propel implant delivers an anti-inflammatory steroid after the sinus surgery while its Sinuva implants are used to treat sinus obstruction due to nasal polyps.
"Combining this innovative technology with our established global presence and sales infrastructure will allow us to broaden our capabilities while expanding access to these valuable therapies," said Vince Racano, Medtronic's ENT business president.
The deal values Intersect at $1.1 billion, including debt, and is expected to close toward the end of Medtronic's current fiscal year.
Medtronic expects the deal to be neutral to its adjusted earnings per share in the first 12 months after its close.
Separately, Intersect said its second-quarter revenue jumped a more than two-fold to $27.3 million from a year earlier, powered by increased demand for the two implants as people resumed elective procedures put off during the pandemic.
